Clinical Trials Logo

Filter by:
NCT ID: NCT01485640 Completed - Schizophrenia Clinical Trials

Lurasidone Extended Use Study

Start date: June 2011
Phase: Phase 3
Study type: Interventional

This is an open-label continuation study designed to monitor the safety, tolerability and effectiveness of lurasidone in subjects who have completed participation in a lurasidone extension study (NCT00868959 and NCT01566162) and who may benefit from continued treatment with lurasidone.

NCT ID: NCT01484561 Completed - Clinical trials for Arthritis, Rheumatoid

A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

Start date: April 2012
Phase: Phase 1
Study type: Interventional

The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).

NCT ID: NCT01482884 Completed - Ulcerative Colitis Clinical Trials

Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis

Start date: March 2012
Phase: Phase 2
Study type: Interventional

The study is designed to evaluate the clinical efficacy and safety of tralokinumab as compared to placebo. Investigational product will be administered as subcutaneous injection. All patients will continue background therapy for ulcerative colitis as per local standards of care in addition to investigational product.

NCT ID: NCT01481493 Completed - Clinical trials for Rheumatoid Arthritis

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Start date: December 2010
Phase: Phase 2
Study type: Interventional

The study is conducted in order to find out if repeated doses of the monoclonal (artificially manufactured) antibody BT061 can help arthritis patients whose disease does not sufficiently respond to a treatment with methotrexate (MTX).

NCT ID: NCT01481116 Terminated - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Start date: January 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM). The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM).

NCT ID: NCT01480245 Terminated - Clinical trials for Muscular Dystrophies

Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

Start date: September 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to explore long-term safety, tolerability and efficacy of GSK2402968 in DMD subjects who previously participated in either DMD114117 or DMD114044.

NCT ID: NCT01479244 Completed - Clinical trials for Breast Cancer With Low to Intermediate HER2 Expression

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

PRESENT
Start date: November 2011
Phase: Phase 3
Study type: Interventional

Purpose of this trial: 1. To assess the efficacy and safety of NeuVax™ administered with adjuvant Leukine® (sargramostim, GM-CSF). 2. To evaluate and compare the disease free survival (DFS) in the vaccinated and control subjects.

NCT ID: NCT01478919 Completed - Colorectal Cancer Clinical Trials

Risk Factors for Residual Neoplasia After Endoscopic Mucosal Resection

Start date: January 2010
Phase: N/A
Study type: Observational

Laterally Spreading Tumors (LST) are important precursosrs of invasive colorectal cancer. Endoscopic treatment has replaced surgery in most of the cases. Nevertheless, after conventional Endoscopic Mucosal Resection (CER), Local Residual Neoplasia (LRN) is an issue. Therefore, endoscopic follow-up and treatment are necessary. To decrease its occurrence, the risk factors of LRN shoudl be identified. Thereafter, in high-risk patients, other modalities of initial treatment including Endoscopic Submucosal Dissection (ESD) and surgical treatment, could be considered. The purpose of this prospective study is to identify risk factors associated with the presence of LRN after CER of LSTs.

NCT ID: NCT01478607 Completed - Clinical trials for Painful Diabetic Peripheral Neuropathy (PDPN)

A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients

PACE
Start date: November 2011
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the safety of repeated applications of QUTENZA in reducing pain intensity in subjects who have peripheral neuropathic pain due to diabetes.

NCT ID: NCT01478594 Completed - Colorectal Cancer Clinical Trials

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Start date: December 2011
Phase: Phase 2
Study type: Interventional

The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and tolerability of tivozanib in combination with mFOLFOX6 and bevacizumab in combination with mFOLFOX6.